Cargando…

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially reduced the lipoprotein(a) levels in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okada, Tomoaki, Miyoshi, Toru, Doi, Masayuki, Nosaka, Kazumasa, Tsushima, Ryu, Ugawa, Satoko, Takagi, Wataru, Sogo, Masahiro, Takahashi, Masahiko, Ito, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144976/ https://www.ncbi.nlm.nih.gov/pubmed/35621864 http://dx.doi.org/10.3390/jcdd9050153

Ejemplares similares

Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure
por: Okada, Tomoaki, et al.
Publicado: (2023)

Secular Decreasing Trend in Plasma Eicosapentaenoic and Docosahexaenoic Acids among Patients with Acute Coronary Syndrome from 2011 to 2019: A Single Center Descriptive Study
por: Okada, Tomoaki, et al.
Publicado: (2021)

Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
por: Oka, Akihiro, et al.
Publicado: (2022)

Lotus root‐like appearance in the left anterior descending artery treated with a drug‐coated balloon angioplasty
por: Takagi, Wataru, et al.
Publicado: (2022)

A successful transfemoral transcatheter aortic valve replacement case with VIABAHN® VBX balloon‐expandable stent‐graft and long Dryseal sheath for challenging access route
por: Kawaguchi, Tomohiro, et al.
Publicado: (2023)

Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention
por: Takagi, Wataru, et al.
Publicado: (2017)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease
por: Choi, Seung Woo, et al.
Publicado: (2022)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis
por: Cheng, Cheng, et al.
Publicado: (2016)

Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris
por: Iwamoto, Mutsumi, et al.
Publicado: (2012)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
por: Toth, Peter P., et al.
Publicado: (2020)

Serial changes in the trends of direct oral anticoagulant use and incidence of thromboembolisms and major bleeding events in very old patients with non-valvular atrial fibrillation
por: Takahashi, Masahiko, et al.
Publicado: (2023)

Relationship Between Endothelial Dysfunction and the Outcomes After Atrial Fibrillation Ablation
por: Okawa, Keisuke, et al.
Publicado: (2023)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis
por: Gao, Ge, et al.
Publicado: (2023)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
por: Abdelmaseih, Ramy, et al.
Publicado: (2021)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
por: Li, Zhenxian, et al.
Publicado: (2023)

The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction
por: Zhao, Qi, et al.
Publicado: (2023)

Cardiovascular events and death after catheter ablation in very old patients with nonvalvular atrial fibrillation
por: Okawa, Keisuke, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
por: Inoue, Ikuo, et al.
Publicado: (2020)

Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?
por: Hang, Shyann, et al.
Publicado: (2021)

EVOLOCUMAB TREATMENT FAILURE FOLLOWING COVID-19 MRNA VACCINATION
por: Park, Byung Joon, et al.
Publicado: (2022)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Safety and Effectiveness of Evolocumab During Acute and Sub-acute Phases of Acute Coronary Syndrome (ACS): A Systematic Review and Meta-analysis
por: Alzarroug, Abdullah F, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2c1deininkgdpntovuvqv5afbo